A method for the high level expression of active lymphotoxin-.beta. receptor immunoglobulin chimeric proteins and their purification
CA 2354539 A1 · Owner: Meier, Werner · Inventors: Meier, Werner; Miatkowski, Konrad; Browning, Jeffrey
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to methods for the expression of high yields of the form protein-immunoglobulin fusions having high affinity binding to its ligand by , culturing hosts transformed with DNA encoding the desired fusions in a cultutre system at a low temperature thereby minimizing the amount of misfolded or misbridged protein forms. Said host cells may be transformed mammalian, insect, yeast or bacterial cells. The protein-immunoglobulin fusion may comprises a member of the TNF or TNF-receptor family such as lymphotoxin-, beta or lymphotoxin-beta receptor. The invention also relates to pharmaceutical composition comprising said protein-immunoglobulin fusions.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 16, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 16, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 16, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.